Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$2.43M-78.87%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- C. Randal Mills
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Beta
- 0.88
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -6.63
Financials
Revenue
$2.43M-78.9%Net Income
$-7.65MEBITDA
$-7.29MFree Cash Flow
$-8.00MEPS (diluted)
$-0.18Shares Outstanding (diluted)
43.62M+326.2%Operating Expenses
$7.35MCash & Debt
$19.90MReturn of Capital
$0.00Revenue by Segment (annual)
$12.29MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $12.29M | $53.38M | $1.29 |
| 2024 | $24.38M | $-53.95M | $-1.86 |
| 2023 | $24.75M | $-37.66M | $-2.07 |
| 2022 | $23.85M | $-32.90M | $-2.38 |
| 2021 | $47.39M | $-24.83M | $-2.38 |
| 2020 | $42.68M | $-21.82M | $-2.13 |
| 2019 | $42.90M | $-11.94M | $-1.12 |
| 2018 | $39.04M | $-11.57M | $-1.08 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.89
- Implied price
- $34.09
- Return from $0.78
- 112.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $16.95 — today's price is already 95.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 78.2% | 86.3% | 93.2% | 99.3% | 104.7% |
| 3.0% | 87.3% | 95.8% | 103.1% | 109.4% | 115.1% |
| 8.0% | 96.3% | 105.3% | 112.9% | 119.6% | 125.5% |
| 13.0% | 105.4% | 114.8% | 122.8% | 129.8% | 136.0% |
| 18.0% | 114.5% | 124.3% | 132.6% | 139.9% | 146.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
73-38.89%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·4d ago·Negative
…any is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX).
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences.
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.15 per share
Typical surprise -5.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.17 vs $-0.15miss
- Thu, May 14$-0.17 vs $-0.15miss
- Wed, Mar 11$-0.14 vs $-0.14beat
- Thu, Nov 6$-0.01 vs $-0.15beat
- Thu, Aug 14$-0.26 vs $-0.17miss
- Thu, May 8$-0.21 vs $-0.20miss
Estimates and results for ELUT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELUT officers and directors.
- Bought
- $1.3m
- Sold
- —
17 trades
0 trades
- Rakin Kevinbought
- Neels Guido Jbought
- Neels Guido Jbought
- Neels Guido Jbought
- Rakin Kevinbought
- Colpman Davidbought
- Makes Brigidbought
- Mills C Randalbought
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ELUT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.